Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma

Oncolytic virotherapy holds promise for cancer treatment, but the factors determining its oncolytic activity remain unclear. Neutrophil extracellular traps (NETs) are associated with cancer progression, yet their formation mechanism and role in oncolytic virotherapy remain elusive. In this study, we...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 15; no. 1; pp. 131 - 19
Main Authors Dai, Weiwei, Tian, Ruotong, Yu, Liubing, Bian, Shasha, Chen, Yuling, Yin, Bowen, Luan, Yuxuan, Chen, Siqi, Fan, Zhuoyang, Yan, Rucheng, Pan, Xin, Hou, Yingyong, Li, Rong, Chen, Juxiang, Shu, Minfeng
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 02.01.2024
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Oncolytic virotherapy holds promise for cancer treatment, but the factors determining its oncolytic activity remain unclear. Neutrophil extracellular traps (NETs) are associated with cancer progression, yet their formation mechanism and role in oncolytic virotherapy remain elusive. In this study, we demonstrate that, in glioma, upregulation of IGF2BP3 enhances the expression of E3 ubiquitin protein ligase MIB1, promoting FTO degradation via the ubiquitin-proteasome pathway. This results in increased m6A-mediated CSF3 release and NET formation. Oncolytic herpes simplex virus (oHSV) stimulates IGF2BP3-induced NET formation in malignant glioma. In glioma models in female mice, a BET inhibitor enhances the oncolytic activity of oHSV by impeding IGF2BP3-induced NETosis, reinforcing virus replication through BRD4 recruitment with the CDK9/RPB-1 complex to HSV gene promoters. Our findings unveil the regulation of m6A-mediated NET formation, highlight oncolytic virus-induced NETosis as a critical checkpoint hindering oncolytic potential, and propose targeting NETosis as a strategy to overcome resistance in oncolytic virotherapy. The m6A reader IGF2BP3 is upregulated in various cancer, including glioblastoma. Here the authors report that IGF2BP3 facilitates NETosis and glioma survival as well as resistance to oncolytic herpes simplex virotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-023-44576-2